Zimmer Biomet stock (US98956P1021): Orthopedic device maker reports Q1 results and raises full-year guidance

Zimmer Biomet shares move after the orthopedic device maker reports first-quarter earnings and raises its full-year revenue and EPS outlook.

Zimmer Biomet stock edged higher after the orthopedic device maker reported first?quarter 2026 results that beat Wall Street expectations and announced an upward revision to its full?year revenue and earnings guidance, signaling continued strength in joint?replacement and spine procedures.

The company posted first?quarter revenue of about 1.64 billion USD, up roughly 5 percent year?over?year on a constant?currency basis, according to Zimmer Biomet's Q1 2026 earnings release as of April 29, 2026. Adjusted earnings per share came in at 1.18 USD, above the prior?year quarter and ahead of the consensus estimate compiled by major financial data providers.

Management attributed the growth to higher volumes in hip and knee implants, continued demand for spine and trauma products, and improved pricing discipline in key markets. The company also highlighted progress on its digital and robotics?enabled platforms, which now contribute a growing share of procedure?related revenue.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zimmer Biomet Holdings, Inc.
• Sector/industry: Medical devices, orthopedics
• Headquarters/country: Warsaw, Indiana, United States
• Core markets: United States, Europe, Asia?Pacific
• Key revenue drivers: Hip and knee implants, spine and trauma devices, digital and robotic?assisted surgery platforms
• Home exchange/listing venue: New York Stock Exchange (ticker: ZBH)
• Trading currency: USD

Zimmer Biomet: core business model

Zimmer Biomet designs, manufactures, and markets a broad portfolio of orthopedic implants and related surgical products used in joint?replacement, spine, trauma, sports medicine, and dental procedures. The company’s business model centers on recurring demand for implants and instruments, supported by long?term relationships with hospitals, ambulatory surgery centers, and surgeons.

The firm generates the majority of its revenue from hip and knee replacement systems, which are typically implanted in patients with osteoarthritis or other degenerative joint conditions. These procedures are largely elective but have shown resilience over time, supported by an aging population and rising obesity rates in developed markets.

Beyond traditional implants, Zimmer Biomet has invested heavily in digital and robotic?assisted surgery platforms, including navigation systems and robotic arms that help surgeons plan and execute joint?replacement procedures with greater precision. These technologies are increasingly bundled with implants and instruments, creating higher?value procedure packages and longer?term customer lock?in.

Main revenue and product drivers for Zimmer Biomet

Hip and knee implants remain the largest revenue drivers for Zimmer Biomet, accounting for well over half of total sales in recent years. The company competes with other large orthopedic players such as Stryker, Johnson & Johnson’s DePuy Synthes, and Smith & Nephew, focusing on differentiated implant designs, materials, and surgical workflows.

Spine and trauma products represent the next?largest segment, benefiting from an aging population and higher rates of spinal?related conditions and fractures. Zimmer Biomet’s spine portfolio includes interbody devices, fixation systems, and minimally invasive solutions, while its trauma business supplies plates, screws, and other fixation hardware for fractures and complex injuries.

Digital and robotic?enabled platforms are a growing but still smaller share of revenue. The company’s ROSA and other navigation systems are used in both knee and spine procedures, and management has indicated that adoption is accelerating in the United States and certain European markets. These platforms typically generate recurring revenue from disposable instruments, software updates, and service contracts.

Why Zimmer Biomet matters for US investors

Zimmer Biomet is of particular interest to US investors because it is headquartered in Indiana and derives a substantial portion of its revenue from the United States, where reimbursement for joint?replacement procedures is relatively stable and demand is underpinned by demographic trends. The company’s listing on the New York Stock Exchange also provides direct access for retail and institutional investors.

For investors focused on healthcare and medical?device exposure, Zimmer Biomet offers a leveraged play on elective surgical volumes and the ongoing shift toward value?based care and technology?enabled procedures. The stock’s performance tends to reflect not only procedure volumes but also pricing dynamics, regulatory developments, and competitive intensity in the orthopedic space.

US investors may also view Zimmer Biomet as a proxy for broader trends in hospital capital spending and adoption of robotics and digital tools in surgery. As more procedures move to outpatient settings and payers emphasize cost?effectiveness, the company’s ability to demonstrate improved clinical outcomes and efficiency gains will be a key factor in sustaining growth.

Conclusion

Zimmer Biomet’s first?quarter results and raised full?year guidance reflect ongoing demand for orthopedic implants and growing traction for its digital and robotic?assisted surgery platforms. The company continues to benefit from an aging population and steady procedure volumes in key markets, particularly the United States.

At the same time, Zimmer Biomet faces competitive pressures, pricing scrutiny, and the need to invest in innovation and commercial execution to maintain market share. For US investors, the stock offers exposure to a mature but evolving medical?device segment, where long?term growth will depend on technology adoption, regulatory outcomes, and reimbursement trends.

As with any equity investment, Zimmer Biomet carries risks related to earnings volatility, regulatory changes, and broader macroeconomic conditions. Investors should weigh these factors against the company’s fundamentals and their own risk tolerance before making any decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.